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3Abstract 
Background: Classical and 11-oxygenated androgens both contribute to the androgen pool. 
Regular monitoring of the androgen status is required in disorders of steroidogenesis and 
multiplexing of androgens improves the diagnostic ability of an assay. Due to the cheap non-
invasive collection, saliva is advantageous when multiple samples are required. Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) offers sensitive, simultaneous 
quantification of steroids with short run times. Here, we have developed an LC-MS/MS assay 
for the simultaneous measurement of 17-hydroxyprogesterone, androstenedione, 
testosterone, 11-hydroxyandrostenedione and 11-ketotestosterone in saliva.
Methods: Samples (300 L unstimulated whole saliva) were prepared by supported liquid 
extraction with dichloromethane and were reconstituted in 40% methanol. After on-line solid 
phase extraction with C18 cartridges, liquid chromatography was performed on a C8 column 
using a water/methanol gradient containing 0.1% formic acid and 2 mmol/L ammonium 
acetate. A Waters TQ-S mass spectrometer was used for quantification.
Results: Total run time was 6.4 minutes. For all analytes recovery was between 89% and 
109%, ion suppression between 86% and 105%. Intra- and inter-assay comparisons showed a 
coefficient of variation <10% and the bias between measured and nominal concentration 
varied between -8% and 10%. Interference with a large set of natural and synthetic steroids 
was excluded. The assay was applied for the measurement of the androgen profile in healthy 
men (n=17) and women (n=10) which confirmed the sensitivity of the assay to be appropriate. 
Conclusion: We present a novel LC-MS/MS assay for the comprehensive profiling of classical 
and 11-oxygenated androgens with potential for routine clinical application.
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4Introduction
The determination of androgen status in female and male patients with disorders of 
steroidogenesis, in particular in congenital adrenal hyperplasia (CAH), is essential to assess 
the quality of their treatment and to stratify their androgen-related cardio-metabolic risk. 
However, adrenal and gonadal androgen biosynthesis are complex and there is extensive 
peripheral activation of androgen precursors (1). Multiplexing of analytes is therefore 
required to improve the diagnostic ability of an androgen assay (2-4). The simultaneous 
measurement of the classical androgen testosterone and its precursor androstenedione in 
serum or saliva has previously been established as a sensitive marker for metabolic risk in 
polycystic ovary syndrome (PCOS), a syndrome of androgen excess in women (2, 5-7).
Additionally, recent research on androgen biosynthesis pathways has identified the class of 
11-oxygenated androgens as a significant driver of androgenic activity in addition to the 
classical androgens like testosterone (8). The 11-oxygenated androgen pathway is initiated by 
adrenal conversion of androstenedione to 11-hydroxyandrostenedione (11OHA4), a major 
adrenal androgen precursor (9). 11OHA4 can be further converted to 11-ketotestosterone 
(11KT), which activates the androgen receptor with the same potency and efficacy as 
testosterone (10, 11). In both common (PCOS) and rare (CAH) androgen excess conditions, 
11-oxygenated androgens make the major contribution to the circulating androgen pool (12-
15). It is therefore essential to include these analytes in the routine assessment of androgen 
status. Treatment monitoring in CAH requires regular and frequent sample collections and 
analysis. The collection of saliva for steroid analysis represents an excellent option for this, as 
it can be conducted by the patients on their own and at home, without the need for clinic 
attendance or support by clinical personnel. Additionally, a significant proportion of 
androgens in circulation is bound to sex-hormone binding globulin and therefore considered 
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5bio-inactive according to the free hormone hypothesis (16). Levels in saliva, however, 
represent the free, unbound fraction of the hormone and more likely reflect bioactive 
concentrations (17). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is 
currently the tool of choice for steroid analysis due to its outstanding selectivity and short run 
times (18, 19). Additionally, LC-MS/MS has the sensitivity to accurately quantify low analyte 
levels, as are expected in saliva, and allows for multiplexing of analytes of interest.
We, therefore, developed and validated an LC-MS/MS assay for the simultaneous 
measurement of the classical androgens testosterone and androstenedione and the 11-
oxygenated androgens 11OHA4 and 11KT. Additionally, the assay includes 17-
hydroxyprogesterone (17OHP), which is the accepted reference standard for the diagnosis 
and monitoring of treatment efficiency in CAH (20, 21). The structures of the analytes are 
shown in Figure 1. This specific combination of analytes in the presented assay can 
comprehensively support the assessment of androgen status in both female and male 
patients with disorders of androgen excess and deficiency.
Material, subjects and methods
Collection of saliva samples
Unstimulated whole saliva was collected by the passive drool technique as previously 
described (22). The passive drool technique was chosen because commercially available 
collection devices, like Salivettes®, can affect analyte recovery and results of the 
measurement due to unspecific adsorption of non-polar steroids such as testosterone  (23, 
24).  To avoid blood or other contaminations of the sample, participants were asked to avoid 
brushing teeth two hours before the sample collection, avoid eating one hour before the 
sample collection and to rinse their mouth with water 10-15 min prior to sample collection. 
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6Immediately after collection samples were frozen at -20 °C. Samples were thawed, 
centrifuged at 2,500g for 5-10 min and the clear supernatant was aliquoted and stored at -80 
°C for analysis. 
The use of human saliva samples has been ethically approved by the Science, Technology, 
Engineering and Mathematics Ethical Review Committee of the University of Birmingham 
(ERN_17-0494). All participants gave written informed consent prior to the sample collection. 
Samples were anonymised and no identifying information was available at the laboratory. 
Healthy volunteers provided morning samples collected between awakening and 10 a.m. 
Male participants (n=17) were between 20 and 35 years of age. Female participants (n=10, 
age range 26-39) had a regular menstrual cycle, did not take oral contraceptives and collected 
the sample on day 21 of the menstrual cycle. The start of the menstrual bleed was defined as 
day 1.
Preparation of stock solutions, standards and QCs
17OHP, androstenedione and testosterone were purchased as solutions in methanol 
(Cerilliant, Sigma Aldrich, Poole, UK). 11OHA4 and 11KT were purchased as powder (Sigma 
Aldrich, Poole, UK). Stock solutions were prepared by dissolving or diluting the respective 
steroid in ultra-pure methanol (Fluka, Poole, UK) and were stored at -20 C. Two separately 
prepared stock solutions were used for the preparation of standards and quality controls 
(QCs) by dilution in a surrogate saliva matrix consisting of phosphate-buffered saline (pH 7.4) 
supplemented with 0.1% (w/v) bovine serum albumin (PBS/BSA). The standards and QCs 
contained a mixture of all analytes at the desired concentrations. Nine standards including a 
zero sample without analytes were used. Concentrations are summarised in Table 1. The 
internal standard mixture in methanol contained [13C3]-(2,3,4)–17-alpha-
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7hydroxyprogesterone ([13C3]-17OHP; Cerilliant, Round Rock, USA), D7-(2,2,4,6,6,16,16)-4-
androstene-3,17-dione (D7- androstenedione; CDN isotopes, Pointe-Claire, Canada), [13C3]-
(2,3,4)-testosterone (Isosciences, King of Prussia, USA), D7-2,2,4,6,6,16,16-4-androsten-11β-
ol-3,17-dione (D7-11OHA4; CDN Isotopes , Pointe-Claire, Canada), D3-16,16,17-11-
ketotestosterone (D3-11KT; Isosciences, Philadelphia, USA).
Sample preparation by Supported Liquid Extraction 
Samples were extracted by Supported Liquid Extraction (SLE) in a 96-well format and a set of 
standards and QCs was added to each plate. 300 µL of saliva sample, standard or QC were 
pipetted into the wells of a 2-mL square well 96-well plate (Porvair, Leatherhead, UK). 20 µL 
of the internal standard (IS) mixture (Table 1) in methanol was added using an Eppendorf 
multipette. The plate was mixed for 1 minute. Samples were transferred onto the wells of a 
SLE plate (SLE+, Biotage, Uppsala, Sweden) and a vacuum was applied to draw the entire 
sample into the matrix of the plate. The plate was incubated at room temperature for 20 
minutes. For elution a fresh 96-well plate was placed under the SLE plate and 1 mL 
dichloromethane (Chromasolv Plus, Sigma Aldrich, Poole, UK) was added onto each well of 
the SLE plate. The solvent was allowed to pass through into the collection plate until no 
residual solvent was visible on the wells. Subsequently positive pressure was applied for 30 
seconds to transfer the remaining solvent into the collection plate. The dichloromethane was 
evaporated using a Vacmaster 96 (Biotage, Uppsala, Sweden) and samples were reconstituted 
in 100 L 40% (v/v) ultra-pure methanol in ultra-pure Milli-Q water (Merck-Millipore, 
Hertfordshire, UK).
Online solid phase extraction and Liquid chromatography
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8Online solid phase extraction and chromatography were carried out using a Waters Online 
SPE Manager coupled to an Acquity ultra high pressure liquid chromatography system 
(Waters, Manchester, UK). A Waters XBridge C18 cartridge was conditioned with 0.5 mL 
methanol and equilibrated with 0.5 mL water. 50 L sample were injected onto the cartridge 
using 0.5 mL water. The cartridge was washed with 0.25 mL 30% (v/v) methanol in water and 
the analytes were subsequently eluted onto the analytical Kinetex® C8 column (100 x 3 mm, 
2.6 µm; Phenomenex, Torrance, USA) using 55% of mobile phase A (2 mmol/L ammonium 
acetate in 0.1% (v/v) formic acid in distilled Milli-Q water) and 45% of mobile phase B (2 
mmol/L ammonium acetate in 0.1% formic acid in ultra-pure methanol). The flow rate was 
0.45 mL/min and the column temperature was 45°C. For chromatographic separation a linear 
gradient from 45 to 85% mobile phase B over 4 minutes was applied; followed by one minute 
at 100% B and one minute of re-equilibration at starting conditions. The eluate was directly 
injected into the mass spectrometer.
Mass spectrometry
Quantification was performed on a Waters XEVO TQ-S mass spectrometer operated in 
positive ion mode. The source offset was maintained at 30 V with a source temperature of 
150 C. The capillary voltage was 0.75 kV and the desolvation temperature and gas flow were 
550C and 1200 L/h. Multiple reaction monitoring mode was used with a dwell time of 0.016 
s. All mass transitions are summarised in Table 1 together with respective cone voltages and 
collision energies. MassLynx NT 4.1 software was used for system control and the MassLynx 
TargetLynx programme for data processing. Peak height ratios of analyte and IS, 1/x weighting 
and linear least square regression were used to produce the standard curves.     
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9Validation
The assay was validated according to accepted guidelines (25, 26).
Matrix effect. Several saliva samples (n=5 for 17OHP, androstenedione and testosterone; n=6 
for 11OHA4 and 11KT) or distilled water were extracted by SLE as described above. Dried 
extracts were reconstituted in 100 µL of 40% methanol and spiked with 10 μL of a steroids 
stock in methanol resulting in the final concentrations indicated in Table 2. As a background 
control to determine the signal from the non-spiked sample, a corresponding volume of water 
was added to the reconstituted extract of saliva samples or water. The matrix effect was 
calculated from the peak height determined in extracts of saliva compared to peak height 
determined in the extract of water after deducting the respective background signal: 100-
[(heightH2O-heightsaliva)/ heightH2O]*100. Matrix effects between 80% and 120% were 
considered acceptable.
Recovery. Recovery includes extraction efficiency and matrix effects. Different saliva samples 
(n= 5 for 17OHP, androstenedione and testosterone; n=6 for 11OHA4 and 11KT) or 50% (v/v) 
methanol were spiked with different concentrations of the analytes. As a background control 
for analyte levels before spiking, an equivalent volume of water was added to the samples. 
The samples were extracted as described above. Recovery was calculated from the 
concentrations measured in saliva compared to the concentrations measured in 50% (v/v) 
methanol deducting the respective background control. A recovery between 80% and 120% 
was considered acceptable.
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10
Specificity. Solutions of common endogenous and synthetic steroids were prepared at 
supraphysiological concentrations in 50% (v/v) methanol in distilled water and analysed, after 
direct injection, for interference in all channels (Table 1) at the relevant retention times. The 
following steroids were tested: 21-deoxycortisol, aldosterone, corticosterone, cortisol, 
cortisone, DHEA, dexamethasone, pregnenolone, DHEAS, budesonide, fludrocortisone, 
fludrocortisone acetate, fluocinolone, triamcinolone, triamcinolone acetonide, prednisolone, 
prednisone, 21-hydroxyprogesterone, epitestosterone, beclomethasone, 11-deoxycortisol, 
dihydrotestosterone, cyproterone acetate, levonorgestrel, desogestrel, norethisterone and 
ethinylestradiol.
Dilution linearity. Different saliva samples (n=6 for 17OHP, androstenedione and 
testosterone; n=4 for 11OHA4 and 11KT) were spiked with the top concentration of the 
standard range for the respective analyte (see Table 1) and serially diluted (factor 2) with 
PBS/BSA. Measured concentrations were plotted against calculated theoretical 
concentrations and curves were judged linear if the correlation coefficient of linear regression 
(R2) was >0.9900. The bias between calculated theoretical and measured concentrations was 
calculated and a bias ≦10% was considered acceptable.
Precision and bias. Saliva samples with three different concentrations and PBS/BSA-based 
samples spiked with different concentrations of the analytes were analysed in ten different 
runs to assess inter-assay imprecision as well as ten times within the same run for intra-assay 
imprecision. The saliva samples were pooled female saliva, pooled male saliva and pooled 
mixed male and female saliva to allow to cover the range of concentrations and get the 
volume required for replicate analysis. The percentage coefficient of variation (CV) calculated 
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11
from the ratio of standard deviation and mean. The bias (spiked PBS/BSA-based samples only) 
was calculated as percentage deviation between the mean observed and nominal 
concentrations. CV and bias were considered acceptable if ≦10%.
Lower limit of quantification (LLOQ). The lower limit of quantification was defined as the 
lowest concentration for which 10 replicates of PBS/BSA based samples gave a bias and CV of 
less than 20%. 
Post-extraction stability. Saliva samples (n=17 for 17OHP, n=18 for androstenedione, n=16 for 
T, n=10 for 11OHA4 and 11KT) were extracted in duplicate and reconstituted for analysis. The 
first plate was measured immediately after extraction, while the second plate was stored in 
a refrigerator for and overnight period before being analysed (10 °C for 22h for 17OHP, 
androstenedione and testosterone or at 4 °C for 18h for 11OHA4 and 11KT). Percentage bias 
between the results of the two measurements was calculated.      
Carry-over. A PBS/BSA-based sample containing 86,667 pmol/L 17OHP, 100,000 pmol/L 
androstenedione, 99300 pmol/L testosterone, 250,000 pmol/L 11OHA4 and 100,000 pmol/L 
11KT was analysed followed by sample containing only PBS/BSA. Percentage carry-over of the 
analytes into the following sample was calculated from the peak height determined for the 
two samples.  
Results
Validation of the analytical performance
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12
All analytes eluted as discrete, identifiable peaks with co-elution of their respective 
deuterated or 13C-labelled IS. Figure 2 shows the chromatograms of a saliva sample. T and 
17OHP co-eluted, but due to the difference in m/z of the parent ions (m/z of 17OHP 331.2 
and 13C3-17OHP 334.2 and m/z testosterone 289.1 and 13C3-testosterone 292.15), no 
interference was observed. The total run time of the assay was 6.4 minutes injection-to-
injection. For each batch, individual standard curves for each analyte were generated by 
plotting the ratio of analyte to IS peak height against the nominal concentrations. Standard 
curves were linear (R2 >0.99) over the entire range given in Table 1 and correlated with the 
respective nominal concentrations with reproducibility between batches. The evaluation of 
matrix effects (n5 different saliva samples) showed percentage signals with mean values 
between 88 and 105% for three different concentrations per analyte and indicated no 
significant ion suppression or enhancement by the saliva matrix (Table 2). For recovery (n5 
different saliva samples), combining extraction efficiency and matrix effects, mean values 
were between 89 and 109.4% for three different concentrations of all analytes (Table 2). 
Interference was excluded for a large set of natural and synthetic steroids (see Material and 
Methods section Specificity for a complete list) for all analyte and IS channels by directly 
injecting supraphysiological concentrations. Serial dilutions of saliva after the addition of the 
analytes at concentrations of the respective highest standard (Table 1) showed linearity with 
R2 values >0.99, when measured concentrations where plotted against the theoretical 
concentrations. The bias between the measured and theoretical concentrations was 1.0  
5.9% for 17OHP, -9.1  10.5% for androstenedione, -2.2  6.9% for testosterone, 8.8  6.3% 
for 11OHA4 and 7.3  4.6% for 11KT. 
The evaluation of the precision of the assay within and between batches is summarised in 
Table 3. For spiked PBS/BSA-based samples, the intra-assay CV was <8.1% and the intra-assay 
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13
bias ranged between -6.6 and 4.2% for all analytes. The respective inter-assay CV was <10.0% 
and the inter-assay bias between -3.1 and 10.2%. For selected saliva samples with three 
different concentrations of each analyte, the intra-assay CV was <6.8% and the inter-assay CV 
was <9.3%. The lower limits of quantification were 12.5 pmol/L for 17OHP (1.875 fmol on 
column), 6.25 pmol/L for androstenedione (0.9375 fmol on column), 5 pmol/L for 
testosterone (0.75 fmol on column), 50 pmol/L for 11OHA4 (7.5 fmol on column), 5 pmol/L 
for 11KT (0.75 fmol on column). Post-extraction stability was tested for overnight storage. 
The bias between the direct and post-storage analysis was between -8.4 and 8.8% for 17OHP, 
-14.9 and 4.9% for androstenedione, -30.6 and 19.9% for testosterone, -8.8 and 4.8% for 
11OHA4 and -8.3 and -0.5% for 11KT. Carry-over was 0.15% for 17OHP, 0.62% for 
androstenedione, 0.65% for T, 0.075% for 11OHA4 and 0.036% for 11KT.
Salivary androgens in healthy volunteers  
We applied the assay to saliva samples collected by healthy male (n=17) and female 
volunteers (n=10) between awakening and 10 a.m. Female participants had a regular 
menstrual cycle and provided samples collected on day 21 of the cycle. Results are 
summarised in Figure 3. Concentrations were above the LLOQ for all samples and analytes. 
For male participants median concentrations (range) were 56 (18-133) pmol/L for 17OHP, 147 
(86-310) pmol/L for androstenedione, 187 (130-320) pmol/L for testosterone, 450 (127-2114) 
pmol/L for 11OHA4, 276 (129-548) pmol/L for 11KT. For female participants median (range) 
values were 117 (27-201) pmol/L for 17OHP, 242 (107-367) pmol/L for androstenedione, 18 
(7-149) pmol/L for testosterone, 448 (201-2039) pmol/L for 11OHA4, 233 (139-535) pmol/L 
for 11KT. As expected, women had higher 17OHP levels than men (p=0.0009), but lower 
testosterone levels (p<0.0001). No differences between men and women were observed for 
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analytes that are primarily of adrenal origin: androstenedione, 11OHA4 and 11KT. 11OHA4 
showed the widest inter-individual variation followed by 11KT.
Discussion 
We present a novel LC-MS/MS assay for the simultaneous measurement of highly clinically 
relevant steroids derived from the classic androgen pathway, androstenedione and 
testosterone, and the 11-oxygenated androgen pathway, 11OHA4 and 11KT, as well as the 
precursor steroid 17OHP in saliva. This specific combination of analytes allows for the 
comprehensive single assay assessment of androgen status including monitoring of 
biochemical control in CAH, which is required over the entire course of life for treatment 
titration and risk stratification. The use of saliva facilitates the collection of multiple samples 
over long periods of time due the simple, self-administered collection technique. While 
previously published assays for salivary androgens were limited to the measurement of 
combinations of testosterone, androstenedione and 17OHP (7, 27-29), our new assay enables 
a complete assessment of the androgen profile, by including 11-oxygenated androgens, which 
have recently been shown to significantly contribute to the circulating androgen burden in 
PCOS and CAH (12, 13). The LLOQs for 17OHP, androstenedione and testosterone of our assay 
are comparable (27, 28) or superior (29) to previously published assays. The short run time of 
the assay (6.4 minutes) compares favourably to other assays (9.5 to 10 min) (27-29) and 
allows for the implementation of the assay into routine practise of clinical laboratories. We 
performed a strict validation of the developed assay that guarantees its accurate, precise and 
reproducible performance according to accepted criteria (25, 26).  The assay was 
demonstrated to be highly selective excluding interference with a large set of natural and 
synthetic steroids. There are no significant effects of the saliva matrix and the assay has 
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excellent recovery, intra- and inter-assay precision and linearity. The high bias between the 
results for testosterone before and after storage of the extracted samples indicate limited 
post-extraction stability of testosterone. If the accurate quantification of testosterone is 
required, the samples thus need to be analysed without post-extraction storage. However, all 
other analytes are stable for an overnight period.
We have successfully applied the assay for preliminary measurements of the salivary 
androgen profile in healthy male and female volunteers. This is the first time 11-oxygenated 
androgens have been measured in saliva. Measured concentrations were above the LLOQ for 
all analytes demonstrating appropriate sensitivity of the assay to quantify the low picomolar 
concentrations in saliva. For androstenedione and testosterone, the presented levels 
compare well to data previously published by our laboratory (5, 7) and others (27, 28). Male 
17OHP levels are also in the same range as previously published, but female 17OHP were 
higher in our samples compared to the data published Mezzullo et al., which can be explained 
by age differences of the participants between the two studies and the collection of our 
samples exclusively on day 21 of the menstrual cycle (28). We observed a comparably high 
degree of inter-individual variability for salivary 11OHA4. 11OHA4 is the second most 
abundant steroid produced by the adrenal gland after DHEAS and a sensitive marker for 
adrenal steroid output (9, 14), which is maximal in the early morning with a subsequent 
decline. The samples in this study have been collected between awakening and 10 a.m. 
Differences in the timing of sample collection within this window are likely to be magnified 
due to the higher morning production rate of 11OHA4 compared to other steroids generated 
by down-stream metabolism in peripheral tissue or, at least in part, primary gonadal 
production; this is a likely explanation for the observed higher variation in salivary 11OHA4. 
It should be noted that, due to the limited number of participants and the limitation of female 
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samples to a specific day of the menstrual cycle, the presented data does not yet allow the 
derivation of reference ranges. 
In conclusion, we have developed and validated a multi-steroid salivary LC-MS/MS assay for 
comprehensive assessment of both classic and 11-oxygenated androgen pathways with high 
potential for routine clinical use for assessment of androgen excess conditions and treatment 
monitoring in CAH.
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Figure legends
Figure 1: Structures of 17-hydroxyprogesterone (17OHP), androstenedione, testosterone, 
11-hydroxyandrostenedione (11OHA4) and 11-ketotestosterone (11KT).
Figure 2: Chromatograms of a saliva sample for all target analytes and their internal 
standards. Quantifier transitions (m/z) are indicated. 17OHP, 17-hydroxyprogesterone; A4, 
androstenedione; T, testosterone; 11OHA4, 11-hydroxyandrostenedione; 11KT, 11-
ketotestosterone.
Figure 3: Morning salivary androgen levels in healthy men (A, n=17) and women (B, n=10). 
Samples were collected between awakening and 10 a.m. Participating women had a regular 
menstrual cycle and collected the sample on day 21 of the cycle. Individual data points, 
median and interquartile range are depicted. 17OHP, 17-hydroxyprogesterone; A4, 
androstenedione; T, testosterone; 11OHA4, 11-hydroxyandrostenedione; 11KT, 11-
ketotestosterone.
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Table 1: Standard and QC concentrations, mass transitions m/z, cone voltages and collision 
energies for target analytes and internal standards.
Standards
(pmol/L)
Quality controls
(pmol/L)
Quantifier transition
Qualifier transition
Cone voltage
(V)
Collision energy
(eV)
Target analyte (MW in g/mol)
17OHP
(330)
0; 8.727; 
87.27; 
174.54; 
436.35; 
872.7; 
1,745.4; 
4,363.5; 
8,727
43.6; 174.25; 697; 6970 331.2 > 97.1
331.2 > 109.1
30
30
22
25
A4
(286)
0; 5.043; 
50.43; 
100.86; 
252.15; 
504.3; 
1,008.6; 
2,521.5; 
5,034
25; 100.5; 402.1; 4021 287.15 > 97.1
287.15 > 109.1
20
20
22
22
T
(288)
0; 5; 50; 
100; 250; 
500; 1,000; 
2,500; 
5,000
25;100; 400; 4000 289.1 > 97.0
289.1 >109.0
32
32
17
22
11OHA4
(302)
0; 25; 250; 
500; 1,250; 
2,500; 
5,000; 
12,500; 
25,000
50; 200; 800; 8000 302.9 > 145.0
302.9 > 97.0
30
30
20
19
11KT
(302)
0; 10; 100; 
200; 500; 
1,000; 
2,000; 
5,000; 
10,000
50; 200; 800; 8000 302.9 > 259.1
302.9 > 121.1 
30
30
20
22
Internal standard (MW in g/mol))
13C3-17OHP
(333)
- - 334.2 > 100.1 30 22
D7-A4
(293)
- - 294.1 > 100.0 20 20
13C3-T
(291)
- - 292.15 > 100.1 32 17
D7-11OHA4
(309)
- - 309.9 > 147.0 30 20
D3-11KT
(305)
- - 305.9 > 262.1 30 22
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Table 2: Recovery and matrix effects. Values indicate the percentage concentration 
(recovery) or percentage height (matrix effect) compared to the respective control samples 
as described in Material and Methods (n=5 for 17OHP, A4 and T; n=6 for 11OHA4 and 11KT).
Analyte Concentration (pmol/L) Recovery (%) Matrix effect (%)
40 104.4 ± 7.1 105 ±13.7
80 105.3 ± 7.3 92.6 ± 13.3
17OHP
400 98.4 ± 11.8 93.0 ± 6.0
40 105.5 ± 14.2 86.0 ± 14.3
80 103.4 ± 11.8 90.1 ± 5.1
Androstenedione
400 102.1 ± 8.4 95.5 ± 7.7
40 108.6 ± 14.0 87.5±17.4
80 109.4 ± 9.5 92.2 ± 15.6
Testosterone
400 102.1 ± 10.4 92.7 ± 4.5
500 89.0 ± 9.2 95.4 ± 7.7
1000 97.1 ± 6.8 98.2 ± 12.1
11OHA4
2000 91.8 ± 4.4 93.7 ± 6.9
250 96.4 ± 6.0 101.5 ± 6.1
500 98.9 ± 3.8 88.0 ± 5.4
11KT
1000 95.0 ± 3.2 89.5 ± 3.8
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Table 3: Intra- and inter-assay precision and bias. Percentage CV was calculated for replicates 
(n=10) of saliva samples and spiked PBS/BSA-based samples. Percentage bias between 
observed and nominal concentrations was calculated for the spiked PBS/BSA-based samples.
Intra-assay precision Inter-assay precision
Saliva samples
Analyte Mean concentration 
observed (pmol/L)
CV (%) CV (%)
18 3.3 8.4
150 1.3 9.2
17OHP
1061 1.6 5.4
133 2.2 2.6
308 1.5 3.7
Androstenedione
695 3.9 3.0
30 2.4 4.0
88 2.2 3.0
Testosterone
392 1.9 7.2
187 5.3 9.3
926 6.8 8.6
11OHA4
2682 5.5 2.9
128 2.3 3.2
397 2.2 3.3
11KT
1358 2.9 3.3
Spiked PBS/BSA-based samples
Analyte Spiked concentration 
(pmol/L)
CV (%) Bias (%) CV (%) Bias (%)
25 8.0 -0.8 5.2 2
50 3.3 -5.1 2.4 0.3
17OHP
100 3.5 -8.2 2.6 -0.4
25 7.4 -4.1 2.6 -2
50 5.9 -4.4 2.1 -1.6
Androstenedione
100 7.6 -6.6 5.2 -2.3
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25 3.7 -4.0 1.8 -3.1
50 3.9 -2.5 1.1 -3
Testosterone
100 3.6 -3.8 3.8 -0.9
300 3.4 -5.2 5.2 8.6
1500 4.4 -3.2 5.6 1
3000 1.5 -3 3.3 2.3
11OHA4
7500 3.7 -3.3 9.95 3.3
60 3.2 1.4 3.6 10.2
300 2.4 2 3.8 5.9
600 1.5 4.2 2.9 4.2
11KT
 
1500 1.5 4 1.9 2.6
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 Figure 1: Structures of 17-hydroxyprogesterone (17OHP), androstenedione, testosterone, 11β-
hydroxyandrostenedione (11OHA4) and 11-ketotestosterone (11KT). 
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 Chromatograms of a saliva sample for all target analytes and their internal standards. Quantifier transitions 
(m/z) are indicated. 17OHP, 17-hydroxyprogesterone; A4, androstenedione; T, testosterone; 11OHA4, 11β-
hydroxyandrostenedione; 11KT, 11-ketotestosterone. 
198x284mm (300 x 300 DPI) 
Page 25 of 26
Annals of Clinical Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Figure 3: Morning salivary androgen levels in healthy men (A, n=17) and women (B, n=10). Samples were 
collected between awakening and 10 a.m. Participating women had a regular menstrual cycle and collected 
the sample on day 21 of the cycle. Individual data points, median and interquartile range are depicted. 
17OHP, 17-hydroxyprogesterone; A4, androstenedione; T, testosterone; 11OHA4, 11β-
hydroxyandrostenedione; 11KT, 11-ketotestosterone. 
239x75mm (300 x 300 DPI) 
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